Nonleadlikeness and leadlikeness in biochemical screening

Drug Discovery Today

Volumn 8, Issue 2, 2003, Pages 86-96

  Rishton, Gilbert M ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM; CHEMICAL COMPOUND; CYCLOSPORIN; CYSTEINE PROTEINASE; HYDROXAMIC ACID; LEAD; PACLITAXEL; PENICILLIN G; PEPTIDE; PHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; SERINE; STEROID; TACROLIMUS; TERPENE; THIOL DERIVATIVE; THREONINE; VANCOMYCIN;

ASSAY; BINDING AFFINITY; BIOASSAY; CHEMICAL ANALYSIS; COVALENT BOND; DRUG BINDING; DRUG SCREENING; LIGAND BINDING; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION; TARGET CELL;

CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037439447     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359644602025722     Document Type: Review

References (20)

1. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23:1997;3-25.
2. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today. 2:1997;382-384.
3. Walters W.P., et al. Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J. Med. Chem. 41:1998;3314-3324.
4. Sadowski J., Kubinyi H.A. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41:1998;3325-3329.
5. McGovern S.L., et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45:2002;1712-1722.
6. Roche O., et al. Development of a virtual screening method for identification of 'frequent hitters' in compound libraries. J. Med. Chem. 45:2002;137-142.
7. Yocum R.R., et al. The mechanism of action of penicillin. Penicillin acylates the active site of Bacillus stearothermophilus D-alanine carboxypeptidase. J. Biol. Chem. 255:1980;3877-3986.
8. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature. 231:1971;232-235.
9. Vane J.R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1:1987;89-96.
10. Vane J.R. The evolution of non-steroidal anti-inflammatory drugs and their mechanisms of action. Drugs. 33:(Suppl. 1):1987;18-27.
11. Rishton, G.M. (1999) Reactive Compounds and In Vitro False Positives. Presented for Vision in Business, Integrated Drug Discovery, Geneva, Switzerland.
12. Sanderson P.E.J. Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19:1999;179-197.
13. Abbenante, G. et al. (2000) Serine and Cysteine Protease Inhibitors: the Suitability of Incorporating an Electrophilic Trap in the Design of Therapeutic Agents. Presented for National Medicinal Chemistry Symposium, Kansas City, MO, USA.
14. Bohm H.J., Schneider G. Virtual Screening for Bioactive Molecules. 2000;Wiley-VCH, Weinheim Germany.
15. Teague S.J., et al. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. Engl. 38:1999;3743-3748.
16. Oprea T.I., et al. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41:2001;1308-1315.
17. Palm K., et al. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14:1997;568-571.
18. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. J. Pharm. Sci. 88:1999;807-814.
19. Ertl P., et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43:2000;3714-3717.
20. Yoshida F., Topliss J.G. QSAR model for drug human oral bioavailability. J. Med. Chem. 43:2000;2575-2585.